menu
    • menu
    [{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Oncology","graph2":"IND Enabling","graph3":"BryoLogyx Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"BryoLogyx Inc \/ BryoLogyx Inc"},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Oncology","graph2":"IND Enabling","graph3":"BryoLogyx Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"BryoLogyx Inc \/ BryoLogyx Inc"},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ Curia","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx Inc \/ Curia"},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx Inc \/ The Division of Cancer Treatment and Diagnosis"}]

    Find Clinical Drug Pipeline Developments & Deals by BryoLogyx Inc

    Menu

    BryoLogyx Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Curia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Sy...

                            Details : In return, under a supply agreement, BryoLogyx will supply Neurotrope with specified amounts of synthetic, Bryostatin-1 will be chemically synthesized by Curia in collaboration with BryoLogyx.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 06, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Curia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Curia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

                            Details : Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 13, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Curia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Neurotrope

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Sy...

                            Details : BryoLogyx has entered into two agreements with Neurotrope for its preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for use in clinical trials and com...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Neurotrope

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            BryoLogyx Inc

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 With National Cancer Insti...

                            Details : BryoLogyx together with National Cancer Institute to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 08, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth